ライフサイエンスコーパス: androgen receptor

1 creased nuclear localization and activity of androgen receptor.

2 ticides are also capable of antagonizing the androgen receptor.

3 their known binding affinities to zebrafish androgen receptor.

4 o the mammary mesenchyme markers ERalpha and androgen receptor.

5 l promoter: demethylation and recruitment of androgen receptor.

6 and correlates with an elevated level of the androgen receptor.

7 ive progestin and a potent activator of fish androgen receptors.

8 al following castration by enhancing p53 and androgen receptor acetylation and in turn sensitizing ca

9 hibition of PI3K causes marked activation of androgen receptor activity.

10 rostate cancer taking abiraterone, and is an androgen receptor agonist, which promotes prostate cance

11 s contained measurable levels of estrogen or androgen receptor agonists nor did they cause reductions

12 develop a weakly binding fragment into novel androgen receptor agonists.

13 activity that is concomitantly modulated by androgen receptor and by CCAAT/enhancer-binding protein

14 hree steroid-responsive genes; vitellogenin, androgen receptor and estrogen receptor alpha.

15 ired for the transcriptional activity of the androgen receptor and its target gene expression.

16 tosterone (DHT), promoting signalling by the androgen receptor and the development of castration-resi

17 d also showed diffusely positive results for androgen receptors and adipophilin in at least 1 of mult

18 Notably, these brain regions are rich in androgen receptors and play a key role in modulating agg

19 original knockout mouse, expression of Ki67, androgen receptor, and Dachshund-1 in prostate epitheliu

20 100 pathogenic polyglutamine repeats in the androgen receptor, and develop a late-onset neuromuscula

21 ty is repressed by the liganded estrogen and androgen receptors, and by the hypothalamic gonadotropin

22 ive tumours express luminal markers, such as androgen receptors, and have a lower proliferative activ

23 Furthermore, competitive androgen receptor antagonism by D4A is comparable to the

24 fically, we bilaterally implanted the potent androgen receptor antagonist flutamide in two key brain

25 osterone was repressed by co-exposure to the androgen receptor antagonist nilutamide supporting a pot

26 Treatment with estrogen and androgen receptor antagonists had opposite effects on Le

27 Androgen receptor (AR) activation is critical for prosta

28 re all highly concordant, as were metrics of androgen receptor (AR) activity and cell cycle activity.

29 BPbeta expression is negatively regulated by androgen receptor (AR) activity and that treatment of an

30 androgen deprivation therapies and increased androgen receptor (AR) activity are major drivers of cas

31 Suppression of androgen receptor (AR) activity in prostate cancer by an

32 Re-activation of androgen receptor (AR) activity is the main driver for d

33 nce microscopy method to measure single cell androgen receptor (AR) activity modulation by antiandrog

34 hboring PCa cells that resulted in increased androgen receptor (AR) activity via promoting AR nuclear

35 Androgen receptor (AR) activity, defined by an AR output

36 ens in muscle, and that intervention with an androgen receptor (AR) agonist will reverse musculoskele

37 Conditional inactivation of androgen receptor (AR) allele using the Rarb-cre transge

38 4-carbonitriles showed potent binding to the androgen receptor (AR) and activated AR-mediated transcr

39 pproach, we find that agonist-liganded human androgen receptor (AR) and antagonist-liganded AR bind t

40 cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required.

41 TSPY and TSPX competitively bind to the androgen receptor (AR) and AR variants, such as AR-V7, a

42 Endogenous TET2 bound the androgen receptor (AR) and AR-coactivator proteins in LN

43 riple-negative breast cancers (TNBC) express androgen receptor (AR) and are potentially responsive to

44 Additionally, interaction between the androgen receptor (AR) and beta-catenin has long been de

45 stasis there is reciprocal activation of the androgen receptor (AR) and beta-catenin in cells of the

46 rentiated acinar adenocarcinoma, with strong androgen receptor (AR) and prostate-specific antigen (PS

47 been associated with alternative splicing of androgen receptor (AR) and specifically, the expression

48 Flutamide is an androgen receptor (AR) antagonist approved by the United

49 cular landscape underpinning response to the androgen receptor (AR) antagonist enzalutamide in patien

50 Androgen receptor (AR) antagonist MDV3100 is the first t

51 Enzalutamide is a potent second-generation androgen receptor (AR) antagonist with activity in metas

52 ecent reports highlight the critical role of androgen receptor (AR) as a regulator of DDR genes, prov

53 t of rapamycin signaling, metastasis and the androgen receptor (AR) axis.

54 te cancer and to (ii) study the mechanism of androgen receptor (AR) binding deregulation induced by t

55 noprecipitation analysis identified putative androgen receptor (AR) binding sites in the proximal pro

56 nomously activates Nkx3.1 expression through androgen receptor (AR) binding to the 11-kb region in bo

57 orm covering both estrogen receptor (ER) and androgen receptor (AR) binding.

58 zalutamide (Enz) can occur through bypass of androgen receptor (AR) blockade by the glucocorticoid re

59 NA-SARCC can post-transcriptionally regulate androgen receptor (AR) by physically binding and destabl

60 ablished that ACK1 regulates the activity of androgen receptor (AR) by tyrosine phosphorylation to fu

61 Polyglutamine (polyQ) expansion of the androgen receptor (AR) causes Kennedy's disease/spinobul

62 f the polyglutamine (polyQ) tract within the androgen receptor (AR) causes neuromuscular degeneration

63 Polyglutamine expansion in the androgen receptor (AR) causes spinal and bulbar muscular

64 a) cells through modulation of the cytosolic androgen receptor (AR) chaperone protein heat shock prot

65 Here we show that the androgen receptor (AR) cistrome undergoes extensive repr

66 c melanoma antigen-A11 (MAGE-A11) is a human androgen receptor (AR) coactivator and proto-oncogene ex

67 Our androgen receptor (AR) conditional transgenic mice devel

68 Androgen receptor (AR) controls the male-specific patter

69 Alteration to the expression and activity of androgen receptor (AR) coregulators in prostate cancer i

70 a myogenic model that overexpresses wildtype androgen receptor (AR) exclusively in muscle fibres and

71 Here, we show that androgen receptor (AR) expression and activity are durab

72 ibited E-cadherin loss and increased stromal androgen receptor (AR) expression.

73 ral androgen biosynthesis and an increase in androgen receptor (AR) expression.

74 Therefore, new strategies to block androgen receptor (AR) function in prostate cancer are r

75 due to a CAG triplet-repeat expansion in the androgen receptor (AR) gene, which is translated into an

76 iplet repeat/polyglutamine expansions in the androgen receptor (AR) gene.

77 lyglutamine (polyQ) repeat expansions in the androgen receptor (AR) gene.

78 Androgen receptor (AR) has a pivotal role in the growth

79 Androgen receptor (AR) has essential roles during prosta

80 Cell type-specific genetic deletions of androgen receptor (Ar) identify a subpopulation of mesen

81 y role for the male gonad, testosterone, and androgen receptor (AR) in CNS remyelination.

82 specific roles and downstream targets of the androgen receptor (AR) in external genitalia.

83 We show that decreased expression of the androgen receptor (AR) in luminal cells of human BPH spe

84 igenetically activating transcription of the androgen receptor (AR) in prostate cancer cells.

85 a critical pioneer transcription factor for androgen receptor (AR) in prostate cancer.

86 This study investigates the role of androgen receptor (AR) in regulating CXCR7.

87 istochemical analysis revealed expression of androgen receptor (AR) in the calcified media of human f

88 tain a unique androgenic phenotype, in which androgen receptor (AR) in the hind limb musculature is e

89 e of this work was to evaluate the effect of androgen receptor (AR) inhibition on prostate-specific m

90 drogen deprivation, but the effectiveness of androgen receptor (AR) inhibitors in recurrent disease i

91 The androgen receptor (AR) is a key factor that regulates th

92 muscular atrophy, proteolysis of the mutant androgen receptor (AR) is a late event.

93 The androgen receptor (AR) is a ligand-activated transcripti

94 The androgen receptor (AR) is a major therapeutic target in

95 Androgen receptor (AR) is a transcriptional activator th

96 s, we generated a novel mouse model in which androgen receptor (AR) is ablated from approximately 75%

97 uman epidermal growth factor receptor 2, the androgen receptor (AR) is also a potential drug target i

98 F-1) domain located in the N-terminus of the androgen receptor (AR) is an attractive therapeutic alte

99 The androgen receptor (AR) is critical for the progression o

100 The androgen receptor (AR) is expressed in more than 70% of

101 ighly expressed in cancer cells in which the androgen receptor (AR) is not detected (AR-), whereas th

102 The androgen receptor (AR) is overexpressed and hyperactivat

103 In prostate cancer (PCa) cells the androgen receptor (AR) is recruited by ELK1, via its ami

104 The androgen receptor (AR) is required for prostate cancer (

105 Polyglutamine expansion in androgen receptor (AR) is responsible for spinobulbar mu

106 The androgen receptor (AR) is the main driver of prostate ca

107 The androgen receptor (AR) is thought to control the express

108 Hormonal regulation of gene expression by androgen receptor (AR) is tightly controlled by many tra

109 Androgen receptor (AR) is widely expressed in different

110 Unexpectedly, TRX1 inhibition also elevates androgen receptor (AR) levels under AD, and AR depletion

111 Androgen receptor (AR) mediates the growth of prostate c

112 pyrrolo[1,2-b]pyrazolines as novel selective androgen receptor (AR) modulators that possess excellent

113 1/2 of green fluorescent protein (GFP) fused androgen receptor (AR) on a tandem array of positive hor

114 rogen-responsive genes without affecting the androgen receptor (AR) or AR-androgen integrity.

115 -AKT pathway in cells expressing full-length androgen receptor (AR) or by specific protein 1 (SP1)-re

116 800 chemicals for estrogen receptor (ER) and androgen receptor (AR) pathway bioactivity.

117 The androgen receptor (AR) pathway is emerging as a potentia

118 The androgen receptor (AR) pathway plays a central role in p

119 Androgen receptor (AR) plays a role in maintaining telom

120 d 100 cases of human melanoma and found that androgen receptor (AR) positive melanoma patients have w

121 The TMPRSS2:ERG gene fusion is common in androgen receptor (AR) positive prostate cancers, yet it

122 ase caused by polyglutamine expansion in the androgen receptor (AR) protein.

123 Here, the authors show that androgen receptor (AR) regulates HR and AR inhibition ac

124 e, and yet, the interaction between YAP1 and androgen receptor (AR) remains unexplored.

125 eading cause of cancer death in men, and the androgen receptor (AR) represents the primary target for

126 ASC-JM17 ameliorates toxicity of the mutant androgen receptor (AR) responsible for SBMA in cell, fly

127 (2015) investigate the relationship between androgen receptor (AR) signaling and beta-catenin/Wnt si

128 ate cancer (CRPC), which is still reliant on androgen receptor (AR) signaling and is associated with

129 cancer (CRPC) is characterized by a shift in androgen receptor (AR) signaling from androgen-dependent

130 showed that coordinated action of miR-21 and androgen receptor (AR) signaling had a critical role in

131 ate cancer (PCa), leading to reactivation of androgen receptor (AR) signaling in a hormone-refractory

132 We found increased activity of androgen receptor (AR) signaling in Fabry disease.

133 Androgen receptor (AR) signaling is a critical pathway f

134 Androgen receptor (AR) signaling is a distinctive featur

135 Androgen receptor (AR) signaling is a key driver of pros

136 Androgen receptor (AR) signaling is a key driver of pros

137 N14 expression was correlated inversely with androgen receptor (AR) signaling output in clinical samp

138 date which modulates multiple targets in the androgen receptor (AR) signaling pathway.

139 cancer is characterized by a dependence upon androgen receptor (AR) signaling, and androgen deprivati

140 state cancers are thought to be hardwired to androgen receptor (AR) signaling, but AR-regulated chang

141 itant activation of oncogenic Kras(G12D) and androgen receptor (AR) signaling, underwent cell differe

142 in prostate tumor initiation and its link to androgen receptor (AR) signaling.

143 e hormonal treatments due to reactivation of androgen receptor (AR) signaling.

144 imens for prostate cancer focus on targeting androgen receptor (AR) signaling.

145 Androgen receptor (AR) splice variants including AR-V7 f

146 of which is to express constitutively active androgen receptor (AR) splice variants lacking the ligan

147 hanism of action of combined cabazitaxel and androgen receptor (AR) targeting in preclinical models o

148 Androgen signals through androgen receptor (AR) to influence prostate development

149 we demonstrate a direct requirement for the androgen receptor (AR) to maintain HR gene expression an

150 dihydrotestosterone (DHT)-induced binding of androgen receptor (AR) to prostate cancer cell enhancers

151 Androgen binds to the androgen receptor (AR) to regulate gene expression, but

152 lly, JMJD1A activity promoted recruitment of androgen receptor (AR) to the c-Myc gene enhancer and in

153 miR-124 targets the androgen receptor (AR) transcript, acting as a tumor sup

154 er (PCa) partly arises due to persistence of androgen receptor (AR) transcriptional activity in the a

155 Moreover, CHK2 depletion increased androgen receptor (AR) transcriptional activity on andro

156 For example, altered androgen receptor (AR) transcriptional programs, includi

157 C is clearly multifactorial, but most often, androgen receptor (AR) upregulation is associated with i

158 Androgen receptor (AR) variants (AR-Vs) expressed in pro

159 gen receptor alpha (ERalpha), as well as the androgen receptor (AR) were analyzed during periods of b

160 by a polyglutamine (polyQ) expansion in the androgen receptor (AR), a transcription factor that is a

161 ILC2Ps express the androgen receptor (AR), and AR signaling inhibits their

162 coexpression of six nuclear receptors (NRs) [androgen receptor (Ar), estrogen receptor alpha (Esr1),

163 e male hormone androgen, working through the androgen receptor (AR), plays a major role in physiologi

164 bserved that CDK5 phosphorylates S308 on the androgen receptor (AR), resulting in its stabilization a

165 circuits that sense endogenous levels of the androgen receptor (AR), the glucocorticoid receptor (GR)

166 As androgens mediate their actions via the androgen receptor (AR), we combined a mouse model of dih

167 We show that PC12 cells harbor endogenous androgen receptor (AR), whose inhibition or silencing st

168 In vitro androgen receptor (AR)-dependent gene transcriptional ac

169 drug enzalutamide by a phenotypic shift from androgen receptor (AR)-dependent luminal epithelial cell

170 Aberrant androgen receptor (AR)-dependent transcription is a hall

171 Androgen receptor (AR)-dependent transcription is a majo

172 reasingly recognized resistance mechanism to androgen receptor (AR)-directed therapy in prostate canc

173 , including widespread disruption of ternary androgen receptor (AR)-FOXA1 and AR-HOXB13 complexes and

174 expression of a previously unreported set of androgen receptor (AR)-independent neuronal genes that a

175 463708 increases binding of ONECUT2, a novel androgen receptor (AR)-interacting transcription factor,

176 Androgen receptor (AR)-mediated gene expression continue

177 TEFb (CDK9/cyclin T) plays a central role in androgen receptor (AR)-mediated transactivation by phosp

178 ed in stem-cell features, as well as variant androgen receptor (AR)-negative neuroendocrine (NE)/smal

179 s and lymph node metastasis showing that the androgen receptor (AR)-positive ccRCC may prefer to meta

180 d activation of progenitor genes, as well as androgen receptor (AR)-target genes.

181 Acquired resistance to androgen receptor (AR)-targeted therapies compels the de

182 or estrogen biosynthesis and ligands for the androgen receptor (AR).

183 moters or enhancers of genes targeted by the androgen receptor (AR).

184 ctivates the transcriptional activity of the androgen receptor (AR).

185 nd-dependent transcriptional activity of the androgen receptor (AR).

186 h has similar DNA-binding specificity to the androgen receptor (AR).

187 lity of these gestagens to transactivate FHM androgen receptor (AR).

188 cer is driven by androgen stimulation of the androgen receptor (AR).

189 a polyglutamine tract in the gene coding for androgen receptor (AR).

190 17 inhibitors can interact directly with the androgen receptor (AR).

191 rally caused by augmented signaling from the androgen receptor (AR).

192 the strict androgen-dependent regulation of androgen receptor (AR): binding of androgen induces stru

193 Androgen receptors (AR) are present in ESC; in other tis

194 Altered androgen-receptor (AR) expression and/or constitutively

195 ee such master regulators (FOXA1, NKX3.1 and androgen receptor, AR) in a primed conversion strategy s

196 her cancer types as well, where CD24 and the androgen receptor are clinically prognostic, given that

197 ccelerates the DNA repair response, binds to androgen receptor at the ERG gene breakpoint and inhibit

198 R models using ToxCast in vitro estrogen and androgen receptor binding data and application in an int

199 lation: in murine models, we determined that androgen receptor binds a conserved region within the ph

200 DHEA increased androgen receptor, c-Fos, and c-Jun recruitment to the m

201 SBMA is due to an androgen receptor containing a polyglutamine tract (ARpo

202 the generation of a novel class of selective androgen receptor degraders (SARDs) to address this resi

203 ated by castration studies and skin-specific androgen receptor deletion in male mice, both of which r

204 In this study, we used a set of androgen receptor deletion mutants to identify the micro

205 tein expression levels of AROM, estrogen and androgen receptors did not differ between males and fema

206 matic benign prostatic hyperplasia (BPH), an androgen receptor-driven, inflammatory disorder affectin

207 cal bone marrow-releasing factors, including androgen receptor, estrogen and matrix metalloproteinase

208 the steroid nuclear hormone receptor family (androgen receptor, estrogen receptor alpha, glucocortico

209 Clinically relevant Ezh2 inhibitors restore androgen receptor expression and sensitivity to antiandr

210 like subtypes were associated with increased androgen receptor expression and signaling, only luminal

211 Here the authors show how androgen receptor expression influences the metastatic r

212 ctions in the expression of vitellogenin and androgen receptor expression.

213 ounds induce degradation of both full-length androgen receptor (fAR) and splice variant AR (AR-V7) to

214 A conditional knockout (cKO) of the androgen receptor gene in PM cells resulted in male infe

215 this group, expression of glucocorticoid and androgen receptor genes explained the most variance in t

216 o those in glucocorticoid receptor (HPA) and androgen receptor (HPG) gene expression.

217 igenic potential of Src and its synergy with androgen receptor in mediating tumor invasion.

218 e demonstrate that LncRNA-SARCC (Suppressing Androgen Receptor in Renal Cell Carcinoma) is differenti

219 ion of JNK1, the alphavbeta6 integrin causes androgen receptor-increased activity in the absence of a

220 t ERG, through its physical interaction with androgen receptor, induces AR aggregation and endoplasmi

221 rase-1 plus androgen receptor is superior to androgen receptor inhibition in metastatic castration-re

222 The androgen receptor inhibitor enzalutamide is approved for

223 Enzalutamide, a potent oral androgen receptor inhibitor, improves survival in men wi

224 Enzalutamide is an oral androgen-receptor inhibitor that has been shown to impro

225 d functional groups known to diminish ligand-androgen receptor interactions.

226 argeting poly (ADP-ribose) polymerase-1 plus androgen receptor is superior to androgen receptor inhib

227 The androgen-receptor isoform encoded by splice variant 7 la

228 nst MDA-MB-453 cells, a model of the luminal androgen receptor (LAR) subtype of TNBC.

229 Binding of androgen receptor leads to changes in the acetylation st

230 onversion of testosterone to the more potent androgen receptor ligand dihydrotestosterone.

231 antagonist nilutamide supporting a potential androgen receptor mediated regulation.

232 , testosterone may exert its effects through androgen receptor-mediated mechanisms or via local aroma

233 rangements occur at DNA breaks formed during androgen receptor-mediated transcription and activate ex

234 n predicted estrogen receptors but relied on androgen receptor-mediated up-regulation of aromatase.

235 iption mediated at least in part by AP-1 and androgen receptor miR-21 promoter interaction.

236 describes different effects of the selective androgen receptor modulator (SARM) nandrolone phenylprop

237 The selective androgen receptor modulator, (S)-(7-cyano-4-(pyridin-2-y

238 only 23 (52%) contained 1 or more selective androgen receptor modulators (Ostarine, LGD-4033, or And

239 lty, we describe a novel series of selective androgen receptor modulators (SARMs).

240 d and sold through the internet as selective androgen receptor modulators and compare the analyzed co

241 Only 52% contained selective androgen receptor modulators and many were inaccurately

242 nalyses of 44 products marketed as selective androgen receptor modulators and sold via the internet,

243 g 44 products marketed and sold as selective androgen receptor modulators, only 23 (52%) contained 1

244 the increasing use of nonsteroidal selective androgen receptor modulators, which have not been approv

245 Products marketed and sold as selective androgen receptor modulators.

246 sers to identify suppliers selling selective androgen receptor modulators.

247 each product marketed and sold as selective androgen receptor modulators.

248 t engagement, evidenced by decreased percent androgen receptor nuclear localization (%ARNL) and incre

249 le network of prostate cells is critical for androgen receptor nuclear translocation and activity.

250 prostate cancer cells in vitro, and homed to androgen receptor-null prostate cancer in vivo.

251 001), NKX3-1 (P = .03), GOLM1 (P = .03), and androgen receptor (P = .04).

252 7 DDR gene sets are strongly correlated with androgen receptor pathway enrichment (rho, range, 0.33 t

253 ter three cycles of chemotherapy (n = 16) or androgen receptor pathway inhibitors (n = 40).

254 filing assay directly targeting genes of the androgen receptor pathway to screen a natural products l

255 ding several haematological malignancies and androgen receptor-positive prostate cancer.

256 n and the relevance of DNA repair processes, androgen receptor programming during prostate carcinogen

257 anscription factors (TFs) in addition to the androgen receptor promises to improve our ability to eff

258 parg mRNA expression and increased placental androgen receptor protein expression.

259 anscriptional activity of glucocorticoid and androgen receptor-protein complexes.

260 le steroidogenic enzymes and antagonizes the androgen receptor, providing an additional explanation f

261 We have previously shown that miR-32 is an androgen receptor-regulated miRNA overexpressed in castr

262 -independent phenotypes by altering the AP-1/androgen receptor regulatory circuit in PCa cells.

263 ombined inhibition of both PI3K isoforms and androgen receptor results in major tumor regressions.

264 treptavidin-binding peptide-tagged wild-type androgen receptor; SBP-AR).

265 tate cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a taxane.

266 This includes an abrogation of androgen receptor signaling and induction of Polycomb Re

267 rtantly, ectopic expression of YAP activated androgen receptor signaling and was sufficient to promot

268 n males than in females due to the different androgen receptor signaling but the molecular mechanisms

269 Androgen receptor signaling fuels prostate cancer and is

270 ies showed regulation of DNA repair genes by androgen receptor signaling in prostate cancers.

271 ated with better OS in patients treated with androgen receptor signaling inhibitors (ARSI), whereas h

272 t SPOP mutation activates both PI3K/mTOR and androgen receptor signaling, effectively uncoupling the

273 cer is lethal when tumors evolve to activate androgen receptor signaling, which circumvents ligand-de

274 MR, and CCNB1) and decreased dependence upon androgen receptor signaling.

275 n vitro and sensitized them to inhibitors of androgen receptor signaling.

276 somatic genomic events in the context of the androgen receptor signaling.

277 strointestinal-lineage genes, independent of androgen-receptor signaling.

278 ents, whereas mutations in genes involved in androgen receptor signalling commonly involve multiple,

279 We previously showed that detection of androgen receptor splice variant 7 (AR-V7) in circulatin

280 nduce PCGEM1, leading to upregulation of the androgen receptor splice variant AR3 which has been show

281 We reported previously that the detection of androgen receptor splice variant-7 (AR-V7) mRNA in circu

282 induces expression of constitutively active androgen receptor splice variants that drive disease pro

283 bjective: To determine if pretherapy nuclear androgen-receptor splice variant 7 (AR-V7) protein expre

284 of cancer-specific transcripts including the androgen-receptor splice variant 7 in a cohort of prosta

285 We hypothesized that detection of androgen-receptor splice variant 7 messenger RNA (AR-V7)

286 Androgen receptor splicing variants (ARVs) that lack the

287 poptosis in various PCa cells independent of androgen receptor status.

288 Molecular analyses implicate aberrant androgen receptor stimulation, biliary acid disturbances

289 Androgen receptor-targeted therapies, including AR agoni

290 itaxel (n = 22); 44.4% received prior potent androgen receptor-targeted therapy.

291 Androgen receptor-targeted treatments for breast cancer

292 Transcription factors NKX3-1, FOXA1 and AR (androgen receptor) tend to occupy these 4C regions.

293 on a 156-residue proteolytic fragment of the androgen receptor that contains a polyQ tract associated

294 ctor YY1, promoting its association with the androgen receptor to drive CD24 expression and cell grow

295 A-485 inhibited the androgen receptor transcriptional program in both androg

296 e prostate cells, including expansion of the androgen receptor transcriptional repertoire, and ERF ha

297 Androgen receptor variants (AR-Vs) provide a mechanism o

298 lphavbeta6 integrin cell surface receptor to androgen receptor via activation of JNK1 and causes incr

299 Androgen receptor was undetectable in the colon or adeno

300 entify the microtubule-binding domain of the androgen receptor, which encompasses the DNA binding dom